Healthcare-associated infections (HAIs) arising in U.S. acute care hospitals cost America as much as $147 billion annually, according to a new report recently published in the Journal of Medical Economics online edition. The report, by MedERA and funded by an unrestricted educational grant from UMF Corporation, estimates for the first time the societal cost of HAIs attributed to acute-care hospitals.
Before this report, economic research into HAIs mostly focused on hospitals or insurers instead of the patients they served, says Albert Marchetti, MD, president and medical director of MedERA. Full societal costs, which are more inclusive than commonly reported direct hospital costs, have never been fully measured or reported. We believe patients rightfully deserve attention, too, because they not only bear out-of-pocket expenses for HAIs but also suffer the unacceptable clinical consequences of heightened morbidity and mortality as well as resultant losses of productivity and wage.
The report, Economic Burden of Healthcare-Associated Infections in U.S. Acute Care Hospitals Societal Perspective, estimates that HAIs cost America from $96 billion to $147 billion annually. Marchetti believes these costs could actually be even higher and calls for new epidemiologic research to update infection rates and patient mortality.
By comparison, an earlier report by the Centers for Disease Control and Prevention (CDC)Â estimated the direct medical costs of HAIs to U.S. hospitals as $28.4 billion to $33.8 billion per year. The MedERA research updates these numbers and calculates the full economic impact of HAIs on all of America one that comprises a toll not only on the hospitals in which they occur but also on others, namely payers, patients and society at large, Marchetti says.
MedERAs estimates are based on 20 years of published data and newly expanded calculations. The total economic burden encompasses direct and indirect costs. Direct costs include hospitalization costs, healthcare professional fees and other medical costs generally billed outside the hospital; nonmedical costs include those related to such things as medical malpractice-wrongful death as well as nonmedical hospital expenses. Indirect costs include lost wages, incapacitation and lost future earnings for patients.
George Clarke, CEO of UMF Corporation, a developer of infection prevention products and programs, says, The MedERA report helps to reveal the true scope and magnitude of the HAI problem in America, which supports our view that HAIs are at epidemic levels. Clearly, immediate intervention is needed to address this problem as rapidly and completely as possible.
Source: UMF Corporation
Vet IP Roundtable 2: Infection Control and Biosecurity Challenges in Veterinary Care
March 31st 2025Veterinary IPs highlight critical gaps in cleaning protocols, training, and biosecurity, stressing the urgent need for standardized, animal-specific infection prevention practices across diverse care settings.
Invisible, Indispensable: The Vital Role of AHRQ in Infection Prevention
March 25th 2025With health care systems under strain and infection preventionists being laid off nationwide, a little-known federal agency stands as a last line of defense against preventable patient harm. Yet the Agency for Healthcare Research and Quality (AHRQ) is now facing devastating cuts—threatening decades of progress in patient safety.
From Shortages to Security: How Reusable Health Care Textiles Can Transform Infection Prevention
March 7th 2025Reusable health care textiles enhance infection prevention, reduce waste, and strengthen supply chains. Hygienically clean textiles offer a sustainable, cost-effective alternative to disposable PPE, ensuring patient safety and environmental responsibility.